Literature DB >> 25528585

SR-BI mediates high density lipoprotein (HDL)-induced anti-inflammatory effect in macrophages.

Gyun Jee Song1, Seong-Min Kim1, Ki-Hoon Park1, Jihoe Kim1, Inho Choi1, Kyung-Hyun Cho2.   

Abstract

High density lipoprotein (HDL) receptor, scavenger receptor class B, type I (SR-BI), mediates selective cholesteryl ester uptake from lipoproteins into the liver as well as cholesterol efflux from macrophages to HDL. Recently, strong evidence has demonstrated the anti-inflammatory effect of HDL, although the mechanism of action is not fully understood. In this study, we showed that the anti-inflammatory effects of HDL are dependent on SR-BI expression in THP-1 macrophages. Consistent with earlier findings, pretreatment of macrophages with HDL abolished LPS-induced TNFα production. HDL also inhibited LPS-induced NF-κB activation. In addition, knockdown of SR-BI or inhibition of SR-BI ligand binding abolished the anti-inflammatory effect of HDL. SR-BI is a multi-ligand receptor that binds to modified lipoproteins as well as native HDL. Since modified lipoproteins have pro-inflammatory properties, it is unclear whether SR-BI activated by modified HDL has an anti- or pro-inflammatory effect. Glycated HDL induced NF-κB activation and cytokine production in macrophages in vitro, suggesting a pro-inflammatory effect for modified HDL. Moreover, inhibition of SR-BI function or expression potentiated glycated HDL-induced TNF-α production, suggesting an anti-inflammatory effect for SR-BI. In conclusion, SR-BI plays an important function in regulating HDL-mediated anti-inflammatory response in macrophages.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammation; ApoA-I; Glycated HDL; HDL; Macrophages; SR-BI

Mesh:

Substances:

Year:  2014        PMID: 25528585     DOI: 10.1016/j.bbrc.2014.12.028

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  ApoA-I/SR-BI modulates S1P/S1PR2-mediated inflammation through the PI3K/Akt signaling pathway in HUVECs.

Authors:  Kun Ren; Yan-Ju Lu; Zhong-Cheng Mo; Xing -Liu; Zhen-Li Tang; Yue Jiang; Xiao-Shan Peng; Li Li; Qing-Hai Zhang; Guang-Hui Yi
Journal:  J Physiol Biochem       Date:  2017-02-08       Impact factor: 4.158

2.  Maternal lipids, BMI and IL-17/IL-35 imbalance in concurrent gestational diabetes mellitus and preeclampsia.

Authors:  Weiping Cao; Xinzhi Wang; Tingmei Chen; Wenlin Xu; Fan Feng; Songlan Zhao; Zuxian Wang; Yu Hu; Bing Xie
Journal:  Exp Ther Med       Date:  2018-05-10       Impact factor: 2.447

Review 3.  SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.

Authors:  MacRae F Linton; Huan Tao; Edward F Linton; Patricia G Yancey
Journal:  Trends Endocrinol Metab       Date:  2017-03-01       Impact factor: 12.015

Review 4.  HDL and Scavenger Receptor Class B Type I (SRBI).

Authors:  Hong Yu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.

Authors:  Jan Novák; Veronika Olejníčková; Nikola Tkáčová; Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

6.  ADAM17 Boosts Cholesterol Efflux and Downstream Effects of High-Density Lipoprotein on Inflammatory Pathways in Macrophages.

Authors:  Vishal Kothari; Jingjing Tang; Yi He; Farah Kramer; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-22       Impact factor: 10.514

Review 7.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

Review 8.  Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging.

Authors:  Linda K Mooberry; Nirupama A Sabnis; Marlyn Panchoo; Bhavani Nagarajan; Andras G Lacko
Journal:  Front Pharmacol       Date:  2016-12-15       Impact factor: 5.810

Review 9.  Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.

Authors:  Peiqiu Cao; Haitao Pan; Tiancun Xiao; Ting Zhou; Jiao Guo; Zhengquan Su
Journal:  Int J Mol Sci       Date:  2015-07-28       Impact factor: 5.923

Review 10.  Importance of Apolipoprotein A-I in Multiple Sclerosis.

Authors:  Lidia A Gardner; Michael C Levin
Journal:  Front Pharmacol       Date:  2015-11-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.